서철원 교수
Dr. Seo Chul Won해당 정보의 수정이나 변경을 희망하는 경우 sungyesacom@gmail.com 문의 부탁드립니다.
학력
1977.03 - 1983.02 서울대학교 의학 학사
1985.03 - 1987.02 서울대학교 의학 석사
1989.03 - 1994.02 서울대학교 의학 박사
경력
1984.03~ 1987.02 서울대병원 내과 전공의
1987.03~ 1989.02 서울대병원 혈액종양내과 전임의
1989.03~ 1990.02 인천중앙길병원 과장
1990.03~ 1991.02 서울아산병원 종양내과 전임의
1991.03~ 1993.03 서울아산병원 종양내과 전임강사
1993.04~ 1997.09 울산의대 서울아산병원 종양내과 조교수
1997.10~ 2002.09 울산의대 서울아산병원 종양내과 부교수
2002.10~ 현재 울산의대 서울아산병원 종양내과 교수
2008.03~ 2012.02 서울아산병원 종양내과 과장
논문
Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL).
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients.
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Electrophysiological features of POEMS syndrome compared to MGUS-related neuropathy.
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
